Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers

Expert Review of Molecular Diagnostics

Volumn 7, Issue 3, 2007, Pages 309-319

  Carney, Walter P ^a,b  

^a SIEMENS CORPORATE RESEARCH   (United States)

^b Oncogene Science   (United States)

Author keywords

Biomarker; Breast cancer; CA9; CAIX; Cancer; EGFR; HER1; HER2 neu; MN; Oncoprotein; Personalized medicine; Targeted therapy

Indexed keywords

CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; OVARY CANCER; PATIENT SELECTION; PROSTATE CANCER; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 34248995010     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.3.309     Document Type: Review

References (60)

1. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price C. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem. 49(10), 1579-1598 (2003).
2. Zhou BB, Peyton M, HE B et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non small cell lung carcinoma. Cancer Cell 10(1-2), 1-12 (2006). • Provides a good overview of extracellular domain cleavage from cancer cells.
3. Cook GB, Neamann IE, Goldblatt JL et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno-1 automated system in breast cancer. Anticancer Res. 21, 1465-1470 (2001).
4. Schippinger W, Regitnig P, Bauernhofer T et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol. Rep. 11, 1131-1136 (2004).
5. Schondorf T, Hoopmann M, Warm M et al. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastasis receiving trastuzumab therapy predict the clinical course. Clin. Chem. 48(8), 1360-1362 (2002).
6. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J. Clin. Oncol. 20(7), 1800-1808 (2002).
7. Lüftner D, Lüke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin. Blochem. 36(4), 233-240 (2003).
8. Köstler WJ, Schwab B, Singer CF et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res. 10, 1618-1624 (2004).
9. Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104(2), 257-563 (2005).
10. Ali SM, Esteva FJ, Fornier M et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S (2006) (Abstract 500).
11. Dinocca S, Blot E, Laberje-le Couteulx S et al. Serum level of HER2 extracellular domain (ECD) is a significant prognostic factor for survival in metastatic breast cancer without HER2 overexpression on primary tumor. Breast Cancer Res. Treat. 100(Suppl. 1), S50 (2006) (Abstract 1035).
12. Esteva FJ, Cheli CD, Fritsche H et al. Clinical utility of serum HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 7(4), R436-R443 (2005). • Describes the decline in serum human epidermal growth factor receptor (HER)2/neu and predicting outcome from trastuzumab therapy.
13. Fornier MN, Seidman AD, Schwartz MK et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel, association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann. Oncol. 16(2), 234-239 (2005).
14. Bethune-Volters A, Labroquere M, Guepratte S et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res. 24 (2C), 1083-1089 (2004).
15. Tse C, Brault D, Gligorov J, Arien S, Neumann R, Capeau J. Evaluation of serum HER-2, CA15-3, and CEA levels as predictive indicators of therapeutic response in metastatic breast cancer (MBC) treated by trastuzumab-based therapy. Clin. Chim. Acta 355(Suppl.), S431 No. WP18.11 (2005).
16. Kashiwaba M, Inaba T, Wakabayaski G. Serum HER-2/neu extra-cellular domain level predicts clinical response in the patients treated with sequential trastuzumab monotherapy and combination with chemotherapy. Breast Cancer Res. Treat. 100(Suppl. 1), S41 (2006) (Abstract 1008).
17. Blackwell KL, Kaplan EH, Franco SX et al. Determining molecular phenotypes of metastatic (GW572016). Breast Cancer Res. Treat. 88(Suppl. 1), 30 (2004) (Abstract 302).
18. Gomez Hl, Chavez MA, Doval DC et al. Updated biomarker results from a phase 2 randomized study of lapatinib as first-line treatment for patients with ErbB2 amplified advanced or metastatic breast cancer. Breast Cancer Res. Treat. 100(Suppl. 68) (2006) (Abstract 1090).
19. Wright C, Cairns J, Cantwell BJ et al. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br. J. Cancer 65, 271-271 (1992).
20. Hayes DF, Yamauchi H, Broadwater G et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer. Clin. Cancer Res. 7, 2703-2711 (2001).
21. Lipton A, Ali SM, Leitzel K et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 20, 1467-1472 (2002).
22. Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol. 21(10), 1967-1972 (2003).
23. Sandri MT, Johansson H, Colleoni M et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res. 24(2C), 1261-1266 (2004).
24. Colomer R, Liombart-Cussac A, Lluch A et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann. Oncol. 15, 201-206 (2004).
25. Manouri C, Hall A, Broglio K et al. Kinetics of serum HER-2/neu changes in pateints with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109, 496-501 (2007).
26. Yuan P, Xu BH, Chu DT. Correlation between serum HER2 oncoprotein and patients with breast cancer. Clin. Med. Sci. J. 19(3), 212-215 (2004).
27. Fehm T, Gebauer G, Jeger W. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res. Treat. 75, 97-106 (2002).
28. Kong SY, Nam BH, Lee KS et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin. Chem. 52(8), 1510-1515 (2006).
29. Zidan J, Dashkovsky I, Stayerman C et al. Comparison of HER2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br. J. Cancer 93 (5), 552-556 (2005). • Nicely reviews the concept and provides considerable proof that primary breast tumors can be HER2/neu negative, while the metastatic tumor from the same patient can be HER2/neu positive.
30. Edgerton SE, Merkel D, Moore DH, Thor AD. HER2/neu/erbB-b2 status by immunohistochemistry and FISH: clonality and regression with recurrence and metastases. Appl. Immunohistochem. Mol. Morphol. 111(3), 214-221 (2003).
31. Gancberg D, DiLeo A, Cardoso F et al. Comparison of HER-2/neu status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 13, 1036-1043 (2002).
32. Lueftner DI, Dilk H, Henschke P et al. Concordance of HER-2/neu expression of primary breast carcinomas and their metachronous distant metastases: results of a 10 year retrospective search in two university institutes of pathology. Breast Cancer Res. Treat. 88(Suppl.), 127 (2004) (Abstract 3045).
33. Regitnig P, Schippinger W, Lindhauer M, Samonigg H, Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J. Pathol. 203(4), 918-926 (2004).
34. Harris LN, Liptcheva V, Broadwater G et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J. Clin. Oncol. 19, 1698-1706 (2001).
35. Tse C, Brault D, Gligorov et al. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and and immunohistochemistry for determining HER-2 status in breast cancer patients. Clin. Chem. 51(7), 1093-1101 (2005).
36. Muller V, Witzel I, Louek HJ et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res. Treat. 86(1), 9-18 (2004).
37. Hoopmann M, Neumann R, Tanasale T, Schondorf T. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study. Anticancer Res. 23, 1031-1034 (2003).
38. Andersen TI, Paus E, Nesland JM et al. Detection of c-erbB-2 related protein in sera from breast cancer patients. Acta Oncol. 34, 499-504 (1995).
39. Molina MA, Codony-Sevrat J, Albanell J, Rojo F, Arrbas J, Baselga J. Trastuzumab (Herceptin®), a humanized anti-HER2 receptor monoclonal antibody inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749 (2001).
40. Ali SM, Leitzel K, Chinchilli VM et al. Relationship of serum HER-2/neu and serum CA15-3 in patients with metastatic breast cancer. Clin. Chem. 48(8), 1314-1320 (2002).
41. Fehm T, Jager W, Kramer S et al. Prognostic significance of serum HER-2/neu and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res. 24, 1987-1992 (2004).
42. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price C. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin. Breast Cancer 5(2), 105-116(2004) • Good review of the serum HER2/neu literature.
43. Isola JJ, Holli K, Oksa H, Terameto Y, Kallioniemi OP. Elevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define and aggressive disease course in patients with breast cancer. Cancer 73, 652-658 (1994).
44. Solomon DS, Branda R, Ciardiellob F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
45. Baron AT, Lafky JM, Boardman CH et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with Stage III or IV epithelial ovarian cancer. J. Cancer Epidemiol. Prev. 8, 129-137 (1999). • First paper to describe the observation that serum epidermal growth factor receptor (EGFR) levels are decreased in cancer.
46. Carney WP, Burrell M, Morris L, Hamer PJ. Normal levels of serum EGFR and decreases in several cancers. Proc. Am. Assoc. Cancer Res. 43, 47 (2003) (Abstract 240).
47. Gregorc V, Ceresoli GL, Floriani I. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 10, 6006-6012 (2004). • Good study that montitored serum EGFR levels in non-small-cell lung cancer patients receiving Iressa®.
48. Marx J, Leitzel K, Al S et al. Serum EGFR in metastatic breast cancer patients. Proc. Am. Assoc. Cancer Res. 21, 436 (2002) (Abstract 1743).
49. Mueller V, Witzel I, Pantel K, Krenkel S, Luck HJ. Prognostic and predictive impact of soluble epidermal growth factor receptor (EGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 26, 1479-1488 (2006).
50. Souder C Leitzel K, Ali SM et al. Serum EGFR/HER-2 predicts poor survival in metastatic breast cancer. Cancer 107(10), 2337-2345 (2006). • Presents data combining two circulating oncoproteins, such as HER2/neu and EGFR, which have the ability to select out patients with the least favorable outcomes.
51. Pastorek J, Pastorekova S, Gallebaut I. Cloning and characterization of MN, a tumour associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9, 2877-2888 (1994).
52. Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family, structure and exon to protein domain relationships. Genomics 33, 480-487 (1996).
53. Wykoff C, Beasley N, Watson P et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60, 7075-7083 (2000).
54. Svastova E, Hulikova A, Rafajovoa M et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577(3), 439-445 (2004).
55. Ivanov S, Liao S, Ivanova A et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158(3), 905-919 (2001).
56. Leppiliampi M, Saarnio J, Karttunen T et al. Carbonic anhydrase Isozymes IX and XII in gastric tumors. World J. Gastroenterol. 9(7), 1398-1403 (2003).
57. Juhasz M, Chen J, Lendeckel U et al. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment. Pharmacol. Ther. 18, 837-846 (2003).
58. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. Anticancer Res. 26, 1479-1488 (2006).
59. Zavada J, Zavadova Z, Zat'ovicova M, Hyrsl L, Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br. J. Cancer 89, 1067-1071 (2003). • First description of the circulating carbonic anhydrase.
60. Sivendran S, Leitzel K, Ali SM et al. Elevated serum MN (carbonic anhydrase) levels in metastatci breast camcer patient sera. Proc. Am. Assoc. Cancer Res. 48, 636 (Abstract 2666) (2007).